Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesSLGL +1.35%55 Net Cash per Share is $13.97 as of Mar. 2026, which is 348% above its 10-year median of 3.12. GuruFocus rates SLGL with a GF Score™ of 55/100 and a GF Value™ of $66.83 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 800 Biotechnology companies, Sol-Gel Technologies ranks worse than 55.13% on this metric.
Sol-Gel Technologies (NAS:SLGL) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Sol-Gel Technologies Net Cash per Share Related Terms
Sol-Gel Technologies Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLGL vs SABS, BCYC, CYDY: Net Cash per Share Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Price-to-Net-Cash falls into.
Sol-Gel Technologies Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Sol-Gel Technologies's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (SLGL) has a Net Cash per Share of $13.97 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sol-Gel Technologies and its competitors. This is 348% above median its historical median of 3.12. Over the past decade, Sol-Gel Technologies' Net Cash per Share has ranged from 0.96 to 8.98. According to the industry distribution chart, Sol-Gel Technologies ranks #441 out of 800 companies in the Biotechnology industry, placing it in the top 55.1%.
Is Sol-Gel Technologies' Net Cash per Share too high?
Sol-Gel Technologies' current Net Cash per Share of $13.97 is 348% above median its 10-year median of 3.12. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 8.98. The Biotechnology industry median Net Cash per Share is 5.39. Sol-Gel Technologies' value of $13.97 is 159.4% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #441 out of 800 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Net Cash per Share compare to SABS and BCYC?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #441 out of 800 companies for Net Cash per Share. This places Sol-Gel Technologies in the lower half of its industry. The industry median Net Cash per Share is 5.39. Sol-Gel Technologies' value of $13.97 is 159.4% above this benchmark. Historically, Sol-Gel Technologies' own Net Cash per Share has ranged from 0.96 to 8.98 over the past decade. While the company's 10-year median is 3.12 vs. the industry median of 5.39, Sol-Gel Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.39, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Net Cash per Share of $13.97 is 159.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Net Cash per Share is $13.97, which is 348% above median its own 10-year median of 3.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $66.83, compared to a current price of $88.00 — trading 31.7% above its estimated fair value. The current Net Cash per Share is $13.97, which is 348% above median its 10-year median of 3.12 and 159.4% above the Biotechnology industry median of 5.39. Sol-Gel Technologies' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Net Cash per Share is $13.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $88.00 is trading 31.7% above its estimated GF Value™ of $66.83.
GuruFocus considers Sol-Gel Technologies to be Significantly Overvalued.
Key valuation signals for SLGL:
Net Cash per Share: $13.97 (348% above median its 10-year median of 3.12)
GF Value™: $66.83 vs. price of $88.00 (31.7% above fair value)
Industry Position: 159.4% above the Biotechnology median (#441 of 800)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score
Get the complete analysis for SLGL
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
